Taj Pharma stands as one of India’s most trusted and globally recognized pharmaceutical companies—celebrated for its world-class quality, regulatory strength, diverse product portfolio, and exceptional manufacturing capabilities. With a strong footprint in Asia, Africa, CIS, LATAM, and the Middle East, the company has established itself as a preferred partner for governments, hospitals, tender authorities, global importers, and international distributors.
Across this chat, you shared a broad range of tablet formulations (Antihyperlipidemic, Anti-diabetic, and other therapeutic segments), along with a robust portfolio of dermatology creams, ointments, and gels. Taj Pharma manufactures ALL these products at WHO-GMP, PIC/S, GLP, and ISO 9001:2018-certified facilities, making the company a premier global supplier for high-demand pharmaceutical formulations.
ANTIHYPERTENSIVE & CARDIOVASCULAR — PRODUCT LIST
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class |
|---|---|---|---|---|---|
| Nebivolol + Valsartan | — | Antihypertensive (Beta-blocker + ARB) | Tablet | 5 mg + 80 mg | Nebivolol: BCS I; Valsartan: BCS II |
| Nebivolol | — | Antihypertensive (Beta-blocker) | Tablet | 2.5 mg, 5 mg | BCS I |
| Nebivolol + Hydrochlorothiazide | — | Antihypertensive (Beta-blocker + Diuretic) | Tablet | 5 mg + 12.5 mg | Nebivolol: BCS I; HCTZ: BCS IV |
| Nebivolol + S-Amlodipine | — | Antihypertensive | Tablet | 5 mg + 2.5 mg | Nebivolol: I; Amlodipine: I |
| Ramipril | — | ACE Inhibitor | Tablet | 2.5 mg, 5 mg | BCS III |
| Ramipril + Hydrochlorothiazide | — | Antihypertensive (ACEI + Diuretic) | Tablet | 2.5/5 mg + 12.5 mg | Ramipril: III; HCTZ: IV |
| Losartan | — | ARB | Tablet | 25 mg, 50 mg | BCS II |
| Losartan + Hydrochlorothiazide | — | Antihypertensive (ARB + Diuretic) | Tablet | 25 mg + 12.5 mg | Losartan: II; HCTZ: IV |
| Losartan + S-Amlodipine | — | Antihypertensive | Tablet | 50 mg + 2.5 mg | Losartan: II; Amlodipine: I |
| Telmisartan | — | ARB | Tablet | 40 mg, 80 mg | BCS II |
| Telmisartan + Hydrochlorothiazide | — | ARB + Diuretic | Tablet | 40 mg + 12.5 mg | Telmisartan: II; HCTZ: IV |
| Telmisartan + Amlodipine + HCTZ | — | Triple Combination Antihypertensive | Tablet | 80+10+25 mg / 40+5+12.5 mg / 20+2.5+6.25 mg | T: II; A: I; HCTZ: IV |
| Telmisartan + Amlodipine | — | ARB + CCB | Tablet | 40/80 mg + 5 mg | Telmisartan: II; Amlodipine: I |
| Telmisartan + Atorvastatin | — | ARB + Statin | Tablet | 20 mg + 5/10 mg; 40 mg + 5/10 mg | Telmisartan: II; Atorvastatin: II |
| Irbesartan | — | ARB | Tablet | 75 mg, 150 mg, 300 mg | BCS II |
| Irbesartan + Hydrochlorothiazide | — | ARB + Diuretic | Tablet | 150/300 mg + 12.5 mg | Irbesartan: II; HCTZ: IV |
| Irbesartan + Hydrochlorothiazide | — | ARB + Diuretic | Tablet | 300 mg + 12.5 mg | Irbesartan: II; HCTZ: IV |
| Olmesartan | — | ARB | Tablet | 5 mg, 10 mg, 20 mg, 40 mg | BCS I |
| Olmesartan + Hydrochlorothiazide | — | ARB + Diuretic | Tablet | 20/40 mg + 12.5 mg | Olmesartan: I; HCTZ: IV |
| Olmesartan + Amlodipine | — | ARB + CCB | Tablet | 10/20/40 mg + 5 mg | Olmesartan: I; Amlodipine: I |
| Olmesartan + Ramipril | — | ARB + ACEI | Tablet | 20/40 mg + 5 mg | Olmesartan: I; Ramipril: III |
| Olmesartan + Atorvastatin | — | ARB + Statin | Tablet | 20/40 mg + 5/10/20 mg | Olmesartan: I; Atorvastatin: II |
| Losartan + Ramipril | — | ARB + ACEI | Tablet | 50 mg + 2.5/5 mg | Losartan: II; Ramipril: III |
| Amlodipine + Valsartan | — | CCB + ARB | Tablet | 5 mg + 40/80/160 mg | Amlodipine: I; Valsartan: II |
| Moxonidine | — | Antihypertensive (Imidazoline Agonist) | Tablet | 0.2 mg, 0.3 mg, 0.4 mg | BCS II (est.) |
| Aliskiren | — | Direct Renin Inhibitor | Tablet | 150 mg, 300 mg | BCS III |
| Cilostazol | — | Antiplatelet | Tablet | 50 mg, 100 mg | BCS II |
| Dronedarone | — | Antiarrhythmic | Tablet | 400 mg | BCS II |
| Azilsartan | — | ARB | Tablet | 40 mg, 80 mg | BCS II |
ANTI-DIABETIC — PRODUCT LIST
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class |
|---|---|---|---|---|---|
| Glimepiride | — | Antidiabetic (Sulfonylurea) | Tablet | 1 mg, 2 mg, 3mg, 4 mg | BCS II |
| Pioglitazone | — | Antidiabetic (Thiazolidinedione) | Tablet | 15 mg, 30 mg, 45 mg | BCS II |
| Miglitol | — | Alpha-Glucosidase Inhibitor | Tablet | 25 mg, 50 mg | BCS III |
| Miglitol + Metformin ER | — | Alpha-Glucosidase Inhibitor + Biguanide | Tablet | 50 mg + 500/1000 mg | Miglitol: III; Metformin: III |
| Glimepiride + Metformin SR | — | Sulfonylurea + Biguanide | Tablet | 1/2 mg + 500 mg | Glimepiride: II; Metformin: III |
| Glimepiride + Metformin SR | — | Sulfonylurea + Biguanide | Tablet | 1/2 mg + 1000 mg | II / III |
| Pioglitazone + Metformin SR | — | Thiazolidinedione + Biguanide | Tablet | 15 mg + 500 mg | P: II; M: III |
| Pioglitazone + Metformin SR | — | Thiazolidinedione + Biguanide | Tablet | 30 mg + 500 mg | II / III |
| Metformin SR + Pioglitazone + Glimepiride | — | Triple Therapy Antidiabetic | Tablet | 500 mg SR + 15 mg + 1/2 mg | M: III; P: II; G: II |
| Voglibose | — | Alpha-Glucosidase Inhibitor | Tablet | 0.2 mg, 0.3 mg | BCS III |
| Voglibose Mouth Dissolving | — | Alpha-Glucosidase Inhibitor | Mouth Dissolving Tablet | 0.2 mg, 0.3 mg | BCS III |
| Voglibose + Metformin SR | — | Alpha-Glucosidase Inhibitor + Biguanide | Tablet | 0.2/0.3 mg + 500 mg | V: III; M: III |
| Vildagliptin | — | DPP-4 Inhibitor | Tablet | 50 mg | BCS III |
| Vildagliptin + Metformin | — | DPP-4 Inhibitor + Biguanide | Tablet | 50 mg + 500/850/1000 mg | V: III; M: III |
(Brand Name kept blank as none provided.)
DIABETIC NEUROPATHY
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Epalrestat | — | Aldose Reductase Inhibitor | Tablet | 50 mg | BCS III |
| Pregabalin | — | Neuropathic Pain (GABA Analog) | Capsule | 75 mg, 150 mg, 300 mg | BCS I |
| Pregabalin + Methylcobalamin | — | Neuropathic Pain | Capsule | 75 mg + 500/750 mcg; 150 mg + 500/750 mcg | Pregabalin: I; Methylcobalamin: III |
ANTI-DEPRESSANT
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Citalopram | — | SSRI | Tablet | 10 mg, 20 mg, 40 mg | BCS I |
| Escitalopram | — | SSRI | Tablet | 5 mg, 10 mg, 15 mg, 30 mg | BCS I |
| Sertraline | — | SSRI | Tablet | 25 mg, 50 mg, 100 mg | BCS II |
| Venlafaxine | — | SNRI | Tablet | 37.5 mg, 75 mg, 150 mg | BCS II |
| Duloxetine | — | SNRI | Capsule | 20 mg, 30 mg, 40 mg, 60 mg | BCS II |
| Milnacipran | — | SNRI | Capsule | 25 mg, 50 mg | BCS I |
| Desvenlafaxine ER | — | SNRI | ER Tablet | 50 mg, 100 mg | BCS I |
| Vilazodone | — | SSRI + 5-HT1A Partial Agonist | Tablet | 20 mg, 40 mg | BCS I |
ANTI-PSYCHOTIC
| Product Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|
| Olanzapine | Atypical Antipsychotic | Tablet | 2.5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg | BCS I |
| Quetiapine | Atypical Antipsychotic | Tablet | 25 mg, 50 mg, 100 mg | BCS II |
| Quetiapine SR | Atypical Antipsychotic | SR Tablet | 50 mg, 150 mg, 200 mg, 300 mg, 400 mg | BCS II |
| Aripiprazole | Atypical Antipsychotic | Tablet | 15 mg, 30 mg | BCS I |
| Amisulpride | Atypical Antipsychotic | Tablet | 50 mg, 100 mg, 200 mg | BCS III |
| Levosulpiride | Prokinetic/Antipsychotic | Tablet | 25 mg, 50 mg, 100 mg | BCS I |
| Ziprasidone | Antipsychotic | Capsule | 20 mg, 40 mg, 60 mg, 80 mg | BCS II |
| Paliperidone ER | Atypical Antipsychotic | ER Tablet | 3 mg, 6 mg, 9 mg | BCS I |
| Zotepine | Atypical Antipsychotic | Tablet | 25 mg, 50 mg, 100 mg | BCS II |
| Iloperidone | Atypical Antipsychotic | Tablet | 1–12 mg | BCS II |
ANTI-FUNGAL
| Product Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|
| Terbinafine | Antifungal | Cream | 1% | BCS II |
| Terbinafine | Antifungal | Tablet | 250 mg | BCS II |
| Voriconazole | Antifungal (Triazole) | Tablet | 50 mg, 200 mg | BCS II |
| Voriconazole Injection | Antifungal | Injection | 200 mg (10 mg/ml) | — |
| Micafungin | Antifungal (Echinocandin) | Injection | — | — |
| Anidulafungin | Antifungal | Injection | — | — |
| Posaconazole | Antifungal | Oral Suspension | — | BCS II |
| Apremilast | PDE4 Inhibitor | Tablet | 10 mg, 20 mg, 30 mg | BCS I |
| Nadifloxacin + Mometasone + Miconazole | Antifungal/Antibacterial/Steroid | Cream | 1% + 0.025% + 1% | — |
| Luliconazole | Antifungal | Cream | 1% | BCS II |
ANTI-HISTAMINIC & ANTI-ASTHMATIC
| Product Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|
| Levocetirizine | Antihistamine | Tablet | 2.5 mg, 5 mg | BCS I |
| Levocetirizine + Montelukast | Antihistamine + Anti-Asthmatic | Tablet | 5 + 10 mg, 2.5 + 4 mg | L: I; M: I |
| Rupatadine | Antihistamine | Tablet | 10 mg | BCS II |
| Rupatadine + Montelukast | Antihistamine + Anti-Asthmatic | Tablet | 10 mg + 10 mg | II / I |
| Olopatadine | Antihistamine | Tablet | 2.5 mg, 5 mg | BCS I |
| Montelukast | Anti-Asthmatic | Tablet | 4 mg, 5 mg, 10 mg | BCS I |
| Ozagrel | Platelet Aggregation Inhibitor | Tablet | 100 mg, 200 mg | — |
| Roflumilast | PDE-4 Inhibitor | Tablet | 500 mcg | BCS II |
| Bilastine | Antihistamine | Tablet | 20 mg | BCS II |
PAIN MANAGEMENT, ANTI-RHEUMATIC & ANTI-INFLAMMATORY
| Product Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|
| Leflunomide | DMARD | Tablet | 10 mg, 20 mg, 100 mg | BCS II |
| Etoricoxib | NSAID | Tablet | 60 mg, 90 mg, 120 mg | BCS II |
| Etoricoxib + Paracetamol | NSAID + Analgesic | Tablet | 60 mg + 500 mg | — |
| Lornoxicam | NSAID | Tablet | 4 mg, 8 mg | BCS II |
| Lornoxicam + Paracetamol | NSAID + Analgesic | Tablet | 4/8 mg + 500 mg | — |
| Etodolac ER | NSAID | ER Tablet | 400 mg, 600 mg | BCS II |
| Amtolmetin Guacyl | NSAID | Tablet | 600 mg | — |
| Tapentadol | Opioid Analgesic | Tablet | 50 mg, 75 mg, 100 mg | BCS I |
| Tapentadol + Paracetamol | Analgesic Combo | Tablet | — | — |
| Aceclofenac + Paracetamol | NSAID + Analgesic | Tablet | 100 mg + 325 mg | — |
GASTROINTESTINAL
| Product Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|
| Lafutidine | H2 Antagonist | Tablet | 5 mg, 10 mg | BCS III |
| Rabeprazole + Itopride SR | PPI + Prokinetic | Capsule | 20 mg + 150 mg | R: III; Itopride: III |
| Rabeprazole | PPI | Tablet | 10 mg, 20 mg, 40 mg | BCS III |
| Rabeprazole + Domperidone SR | PPI + Prokinetic | Capsule | 20 mg + 30 mg SR | — |
| Rabeprazole IV | PPI | Injection | 20 mg | — |
| Omeprazole | PPI | Tablet | 10 mg, 20 mg | BCS II |
| Omeprazole IV | PPI | Injection | 40 mg | — |
| Omeprazole + Domperidone SR | PPI + Prokinetic | Capsule | 20 mg + 30 mg SR | — |
| Lansoprazole | PPI | Capsule | 15 mg, 30 mg | BCS II |
| Lansoprazole + Domperidone SR | PPI + Prokinetic | Capsule | 20 mg + 30 mg SR | — |
| Pantoprazole | PPI | Tablet | 20 mg, 40 mg | BCS III |
| Pantoprazole IV | PPI | Injection | 40 mg | — |
| Pantoprazole + Domperidone SR | PPI + Prokinetic | Tablet/Capsule | 20/40 mg + 30 mg SR | — |
| Pantoprazole + Itopride SR | PPI + Prokinetic | Capsule | 40 mg + 150 mg SR | — |
| Esomeprazole | PPI | Tablet | 20 mg, 40 mg | BCS I |
| Itopride | Prokinetic | Tablet | 50 mg, 150 mg SR | BCS III |
| Cinitapride | Prokinetic | Tablet | 1 mg | BCS III |
| Cinitapride SR | Prokinetic | SR Tablet | 3 mg | BCS III |
| Esomeprazole + Domperidone SR | PPI + Prokinetic | Capsule | 20/40 mg + 30 mg SR | — |
| Racecadotril | Antidiarrheal | Capsule | 100 mg | — |
| Racecadotril | Sachet | Sachet | 10 mg, 30 mg | — |
| Racecadotril DT | Antidiarrheal | DT Tablet | 10 mg, 15 mg, 20 mg, 30 mg | — |
| Ilaprazole | PPI | Tablet | 5 mg, 10 mg | BCS II |
| Rabeprazole + Levosulpiride | PPI + Prokinetic | Capsule/Tablet | 20 mg + 75 mg | — |
| Pancreatin | Digestive Enzyme | Capsule | Multi-strength | — |
| Prucalopride | Prokinetic | Tablet | — | — |
| Acotiamide | Prokinetic | Tablet | — | — |
UROLOGY
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Tamsulosin | Alpha-1 blocker | Capsule/Tablet | 0.2 mg, 0.4 mg | BCS I | |
| Tamsulosin + Finasteride | Alpha-1 blocker + 5-ARI | Capsule/Tablet | 0.4 mg + 5 mg | Tamsulosin: I; Finasteride: II | |
| Tamsulosin + Tolterodine (pellets in capsule) | Alpha-1 blocker + Antimuscarinic | Capsule (pellets) | 0.4 mg + 4 mg (pellets) | Tamsulosin: I; Tolterodine: III | |
| Alfuzosin ER | Alpha-1 blocker | ER Tablet | 10 mg | BCS I | |
| Solifenacin | Antimuscarinic | Capsule | 5 mg, 10 mg | BCS II | |
| Darifenacin ER | Antimuscarinic | ER Tablet | 7.5 mg, 15 mg | BCS II | |
| Trospium chloride SR | Antimuscarinic | SR Capsule | 60 mg | BCS III | |
| Mirabegron | Beta-3 agonist | Tablet | 25 mg, 50 mg | BCS II |
ANTI-BACTERIAL
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Levofloxacin | Fluoroquinolone antibiotic | Tablet | 250 mg, 500 mg | BCS I | |
| Levofloxacin + Ornidazole | Antibiotic + Antiprotozoal | Tablet | 250 mg + 500 mg | — | |
| Balofloxacin | Fluoroquinolone antibiotic | Tablet | 100 mg | BCS I | |
| Linezolid | Oxazolidinone antibiotic | Tablet | 600 mg | BCS I | |
| Gemifloxacin | Fluoroquinolone antibiotic | Tablet | 320 mg | BCS I | |
| Prulifloxacin | Fluoroquinolone antibiotic (prodrug) | Tablet | 600 mg | BCS I | |
| Nadifloxacin (topical) | Fluoroquinolone (topical) | Cream | 1% | — | |
| Nadifloxacin + Clobetasol propionate (topical) | Antibiotic + Steroid | Topical prep | 10 mg + 0.5 mg (per g) | — | |
| Nadifloxacin + Miconazole + Mometasone (topical) | Antibiotic + Antifungal + Steroid | Cream | 10 mg + 20 mg + 1 mg (per g) | — | |
| Ofloxacin + Ornidazole | Antibiotic + Antiprotozoal | Tablet | 200 mg + 500 mg | — | |
| Azithromycin + Ambroxol SR | Macrolide + Mucolytic | Tablet (SR) | 500 mg + 75 mg SR | — | |
| Cefpodoxime | 3rd gen Cephalosporin | Tablet/Chewable/Syrup | 100 mg, 200 mg; DT 50/100 mg; Dry syrup 50 mg/5 ml | BCS III | |
| Cefpodoxime + Clavulanate | Cephalosporin + Beta-lactamase inhibitor | Tablet/Syrup/DT | 100 + 62.5 mg; 200 + 125 mg; syrup/suspensions variants | — | |
| Cefpodoxime + Ofloxacin | Combination antibiotic | Tablet | 100/200 mg + 100/200 mg | — | |
| Cefdinir | 3rd gen Cephalosporin | Capsule/Dry syrup | 300 mg; dry syrup 125 mg/5 ml | BCS III | |
| Cefixime | 3rd gen Cephalosporin | DT/Tablets | 50 mg DT, 100 mg DT, 200 mg film coated | BCS III | |
| Cefixime + Clavulanate | Cephalosporin + Beta-lactamase inhibitor | Tablet/Syrup/DT | 100 + 62.5 mg; 200 + 125 mg; syrup variants | — | |
| Cefixime + Ofloxacin | Combination antibiotic | Tablet | 200 mg + 200 mg | — | |
| Cefixime + Linezolid | Combination antibiotic | Tablet | — | — | |
| Cefuroxime Axetil | 2nd gen Cephalosporin | Tablet | 250 mg, 500 mg | BCS III | |
| Cefuroxime + Clavulanate | Cephalosporin + Beta-lactamase inhibitor | Tablet | 250/125 mg + 125/62.5 mg | — | |
| Cefadroxil + Clavulanate | Cephalosporin + Beta-lactamase inhibitor | Tablet | 500/250 mg + 125/62.5 mg | — | |
| Cefetamate pivoxyl | Cephalosporin (prodrug) | Tablet | 250 mg, 500 mg | — | |
| Cefditoren | 3rd gen Cephalosporin | Tablet | 200 mg | BCS III | |
| Meropenem (inj) | Carbapenem antibiotic | Injection | 500 mg, 1 g | — | |
| Meropenem + Sulbactam (inj) | Carbapenem + Beta-lactamase inhibitor | Injection | 1000 mg + 500 mg | — | |
| Ertapenem | Carbapenem antibiotic | Injection | 1 g | — | |
| Imipenem + Cilastatin | Carbapenem + Dehydropeptidase inhibitor | Injection | 250 mg, 500 mg | — | |
| Faropenem | Oral penem antibiotic | Tablet | 150 mg, 200 mg; ER 300 mg | BCS I | |
| Doripenem (inj) | Carbapenem antibiotic | Injection | 250 mg, 500 mg | — |
ONCOLOGY
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Gemcitabine | Antimetabolite (chemo) | Injection | 200 mg, 500 mg, 1 g | — | |
| Bicalutamide | Antiandrogen | Tablet | 50 mg | BCS II | |
| Imatinib (capsules) | TKI (BCR-ABL) | Capsule/Tablet | 100 mg (capsule); 100 mg, 400 mg (tablet) | BCS II | |
| Capecitabine | Oral prodrug (5-FU) | Tablet | 500 mg, 1 g | BCS I | |
| Anastrozole | Aromatase inhibitor | Tablet | 1 mg | BCS II | |
| Temozolomide | Alkylating agent | Capsule | 20 mg, 100 mg, 250 mg | BCS II | |
| Gefitinib | EGFR TKI | Tablet | 250 mg | BCS II | |
| Aprepitant (kit) | Antiemetic (NK1 antagonist) | Capsule/Kit | 80 mg, 125 mg | BCS II | |
| Ibandronate | Bisphosphonate | Tablet | 25 mg, 50 mg, 150 mg | BCS II | |
| Bendamustine (inj) | Alkylating agent | Injection (vial) | 100 mg/vial | — | |
| Plerixafor (inj) | Hematopoietic stem-cell mobilizer | Injection | 1.2 ml per vial | — | |
| Fosaprepitant (inj) | IV NK1 antagonist | Injection | 150 mg | — |
ANTI-RETROVIRAL (ARV)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Darunavir | Protease inhibitor | Tablet | 75 mg, 150 mg, 300 mg, 400 mg, 600 mg | BCS II | |
| Efavirenz | NNRTI | Tablet | 600 mg | BCS II | |
| Zidovudine (AZT) | NRTI | Tablet/Solution | — | BCS I | |
| Zidovudine + Lamivudine | NRTI combo | Tablet | — | — | |
| Zidovudine + Lamivudine + Nevirapine | NRTI + NNRTI | Tablet | — | — | |
| Stavudine + Lamivudine + Nevirapine | Combination ARV | Tablet/Capsule | — | — | |
| Stavudine (d4T) | NRTI | Capsule | — | — | |
| Lamivudine | NRTI | Tablet/Solution | — | BCS I | |
| Indinavir | Protease inhibitor | Capsule | — | BCS II | |
| Tenofovir + Lamivudine | NRTI combo | Tablet | — | — | |
| Tenofovir + Lamivudine + Efavirenz | Fixed dose combo (TDF/3TC/EFV) | Tablet | — | — | |
| Zidovudine oral solution | NRTI | Oral solution | — | — | |
| Lamivudine oral solution | NRTI | Oral solution | — | — | |
| Abacavir + Lamivudine | NRTI combo | Tablet | 600 mg + 300 mg | — | |
| TAF + Emtricitabine | NRTI combo (TAF/FTC) | Tablet | — | BCS II |
HEPATITIS
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Tenofovir (TDF) | Nucleotide RT inhibitor | Tablet | 300 mg | BCS II | |
| Tenofovir Alafenamide (TAF) | Prodrug of tenofovir | Tablet | 10 mg, 25 mg | BCS II | |
| Sofosbuvir | NS5B polymerase inhibitor | Tablet | 400 mg | BCS II | |
| Sofosbuvir + Velpatasvir | Pan-genotypic DAA combo | Tablet | 400 mg + 100 mg | BCS II | |
| Daclatasvir | NS5A inhibitor | Tablet | 60 mg | BCS II |
OTHER PRODUCTS (IMMUNOMODULATOR, ERECTILE DYSFUNCTION, ETC.)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Thalidomide | Immunomodulator | Capsule/Tablet | 50 mg, 100 mg | — | |
| Lenalidomide | Immunomodulator | Capsule | 5 mg, 10 mg, 15 mg, 25 mg | — | |
| Sildenafil citrate | PDE5 inhibitor (ED) | Tablet | 50 mg, 100 mg | BCS I | |
| Tadalafil | PDE5 inhibitor (ED) | Tablet | 5 mg, 10 mg, 20 mg | BCS II | |
| Febuxostat | Xanthine oxidase inhibitor (gout) | Tablet | 40 mg, 80 mg, 120 mg | BCS II | |
| Raloxifene | SERM (anti-osteoporotic) | Tablet | 60 mg | BCS II | |
| Eszopiclone | Hypnotic (insomnia) | Tablet | 1 mg, 2 mg, 3 mg | BCS I | |
| Ropinirole | Dopamine agonist (Parkinson’s) | Tablet | 0.25 mg, 0.5 mg, 1 mg, 2 mg, 5 mg | BCS II | |
| Rasagiline | MAO-B inhibitor (Parkinson’s) | Tablet | 0.5 mg, 1 mg | BCS II | |
| Pramipexole | Dopamine agonist (Parkinson’s) | Tablet | 0.25 mg, 0.5 mg, 1 mg, 1.5 mg | BCS II | |
| Donepezil | AChE inhibitor (Alzheimer’s) | Tablet | 5 mg, 10 mg | BCS I | |
| Lacosamide | Antiepileptic | Tablet | 50 mg, 100 mg, 150 mg, 200 mg | BCS II | |
| Levetiracetam | Antiepileptic | Tablet/ER/Solution | 250 mg, 500 mg, 750 mg, 1 g; ER 500/750 mg; oral solution 100 mg/ml | BCS I | |
| Zonisamide | Antiepileptic | Capsule | 25 mg, 50 mg, 100 mg | BCS II | |
| Torsemide | Loop diuretic | Tablet | 5 mg, 10 mg, 20 mg, 100 mg | BCS I | |
| Eplerenone | Aldosterone antagonist (diuretic class) | Tablet | 25 mg, 50 mg | BCS II | |
| Prasugrel | Antiplatelet | Tablet | 5 mg, 10 mg | BCS II | |
| Clopidogrel | Antiplatelet | Tablet | 75 mg | BCS II | |
| Dabigatran | Oral anticoagulant (direct thrombin inhibitor) | Capsule | — | BCS I | |
| Ranolazine ER | Antianginal | ER Tablet | 500 mg, 1 g | BCS II | |
| Ivabradine | HR lowering agent (antianginal) | Tablet | 5 mg, 7.5 mg | BCS II | |
| Bosentan | Endothelin receptor antagonist (PAH) | Tablet | 125 mg, 250 mg | BCS II |
GENERAL BLOCK (selected high-volume)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Azithromycin | Macrolide antibiotic | Tablet | 1000 mg; 500 mg; 250 mg | BCS II | |
| Fluconazole | Antifungal | Tablet | 150 mg | BCS II | |
| Sildenafil + Dapoxetine | ED + premature ejaculation combo | Tablet | Sildenafil 50 mg + Dapoxetine 30 mg | — | |
| Famciclovir | Antiviral | Tablet | 250 mg, 500 mg | BCS II | |
| Secnidazole | Nitroimidazole antiprotozoal | Tablet | 1000 mg | — | |
| Fexofenadine | Antihistamine | Tablet | 120 mg, 180 mg; combo with Montelukast 10 mg | BCS I | |
| Etoricoxib | NSAID | Tablet | 90 mg; 60 mg | BCS II | |
| Aceclofenac + Paracetamol + Serratiopeptidase | Analgesic/Anti-inflammatory combo | Tablet | 100 mg + 325 mg + 15 mg | — | |
| Atorvastatin + Fenofibrate | Lipid lowering combo | Tablet | 10 mg + 160 mg | Atorvastatin: II; Fenofibrate: II | |
| Teneligliptin ± Metformin ER | Antidiabetic (DPP-4 inhibitor ± biguanide) | Tablet | Teneligliptin 20 mg; combos with Metformin ER 500/1000 mg | BCS III | |
| Rifaximin | Gut-selective antibiotic | Tablet | 200 mg, 400 mg, 550 mg | — | |
| Mesalamine PR | Anti-inflammatory (IBD) | Prolonged release Tablet | 1200 mg | — | |
| Oxcarbazepine | Antiepileptic | Tablet | 150 mg, 300 mg, 450 mg, 600 mg | BCS II | |
| Rivaroxaban | Oral anticoagulant (Factor Xa inhibitor) | Tablet | 2.5 mg, 10 mg, 15 mg, 20 mg | BCS II | |
| First-line TB FDC (E, H, R, Z) | Antitubercular FDC | Tablet | Standard IP strengths | — | |
| Glipizide | Sulfonylurea (antidiabetic) | Tablet | 5 mg | BCS II | |
| Hydrochlorothiazide | Thiazide diuretic | Tablet | 25 mg | BCS IV | |
| Perampanel | Antiepileptic | Tablet | 2 mg, 4 mg, 6 mg | BCS II | |
| Silodosin | Alpha-1 blocker | Capsule | 4 mg, 8 mg | BCS I | |
| Doxycycline + Lactic Acid Bacillus | Tetracycline antibiotic + probiotic | Capsule | — | — |
Creams & Ointments
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Nanocrystalline Silver Gel | — | Antimicrobial / Wound Care | Film Forming Gel | 0.002% w/w | Not Applicable |
| Luliconazole | — | Antifungal | Cream | 1% w/w | Class II (estimate) |
| Azelaic Acid | — | Anti-acne / Depigmenting | Gel | 10% w/w | Class III (estimate) |
| Azelaic Acid | — | Anti-acne / Depigmenting | Gel | 20% w/w | Class III (estimate) |
| Tretinoin | — | Anti-acne / Keratolytic | Cream | 0.025% w/w | Class IV (estimate) |
| Tretinoin | — | Anti-acne / Keratolytic | Cream | 0.05% w/w | Class IV (estimate) |
| Adapalene + Benzoyl Peroxide | — | Anti-acne Combination | Gel (Microsphere) | 0.1% + 2.5% | Class II/III (estimate) |
| Clotrimazole | — | Antifungal | Cream | 1% w/w | Class II (estimate) |
| Choline Salicylate + Benzalkonium Chloride + Lignocaine | — | Oral Analgesic / Antiseptic Gel | Gel | 8.7% + 0.01% + 2% | Not Applicable |
| Diclofenac + Methyl Salicylate + Capsaicin + Menthol + Linseed Oil | — | Anti-inflammatory / Analgesic | Gel | Multi-ingredient | Not Applicable |
| Centella Asiatica (Film Forming) | — | Wound Healing / Diabetic Ulcers | Gel | 0.5% w/w | Not Applicable |
| Amorolfine | — | Antifungal | Cream | 0.25% w/w | Class II (estimate) |
| Mupirocin | — | Antibacterial | Ointment | 2% w/w | Class III (estimate) |
Taj Pharma: India’s Leading Manufacturer, Supplier & Global Exporter of Premium Creams and Ointments
Taj Pharma stands as one of India’s most trusted names in pharmaceutical manufacturing, offering a comprehensive range of high-quality dermatology creams, ointments, gels, and film-forming formulations. Backed by WHO-GMP and PIC/S compliant facilities, Taj Pharma has earned international recognition for its quality, consistency, and regulatory excellence—making it a preferred partner for governments, hospitals, distributors, and global brands.
Our product portfolio includes advanced formulations such as Luliconazole Cream 1%, Nanocrystalline Silver Film Forming Gel, Azelaic Acid Gel, Tretinoin Cream, Adapalene + Benzoyl Peroxide Gel, Clotrimazole Cream, Mupirocin Ointment, and several specialty wound-care and anti-acne products.
1. State-of-the-Art WHO-GMP Manufacturing for Dermatology Products
Taj Pharma’s dermatological manufacturing facility is equipped with modern production lines dedicated to semi-solid formulations. This ensures high output capacity with international compliance, allowing us to serve clients across Asia, Africa, Latin America, CIS, and the Middle East.
Our facility offers:
- WHO-GMP, ISO 9001:2018 & PIC/S-compliant infrastructure
- Dedicated manufacturing areas for creams, gels, ointments & film-forming technologies
- Imported planetary mixers, homogenizers & vacuum emulsification systems
- Fully validated HVAC and clean-room classifications
- Microbiology, stability and analytical testing laboratories
- EU & US-export compliant packaging solutions
2. Wide Portfolio of Dermatology and Wound-Care Products
Taj Pharma specializes in high-demand formulations used in dermatology, cosmetology, wound management, and anti-fungal/anti-acne therapy. Our product offerings include:
Antifungal Range
- Luliconazole Cream 1%
- Clotrimazole Cream 1%
- Amorolfine Cream 0.25%
Anti-Acne & Dermatology Range
- Azelaic Acid Gel 10% & 20%
- Tretinoin Cream 0.025% & 0.05%
- Adapalene (Microspheres) + Benzoyl Peroxide (Microspheres) Gel
- Centella Asiatica Gel for Diabetic Wounds
Antibacterial & Antiseptic Range
- Mupirocin Ointment 2%
- Choline Salicylate + Benzalkonium Chloride + Lignocaine Gel
Pain Relief & Anti-Inflammatory Gels
- Diclofenac + Methyl Salicylate + Menthol + Capsaicin + Linseed Oil Gel
Advanced Wound Healing Range
- Nanocrystalline Silver Film Forming Gel
This broad-spectrum portfolio positions Taj Pharma as a single-source supplier for international distributors, tender participants, and private label brands.
3. High-Quality Raw Materials & Strict Quality Control
All Taj Pharma products undergo:
- 100% batch traceability
- Validated manufacturing processes
- Microbial limit tests & preservative efficacy tests
- Stability studies (Zone II & IVb)
- Assay and dissolution tests (where applicable)
We use only pharma-grade APIs and excipients from audited suppliers, ensuring consistent quality across global markets.
4. Global Export Strength & Regulatory Support
Taj Pharma is a leading exporter to:
- Middle East (UAE, Oman, Bahrain, Kuwait, Qatar)
- Africa (Kenya, Tanzania, Ghana, Uganda, Nigeria)
- Southeast Asia (Philippines, Vietnam, Myanmar)
- LATAM (Bolivia, Peru, Guatemala, Chile)
- CIS Nations
We provide complete regulatory support, including:
- CTD/ACTD dossiers
- Free Sale Certificate (FSC)
- COPP (WHO Format)
- Stability data
- GMP Certificates
- Artworks & packaging customization
This makes Taj Pharma a preferred partner for tender supplies, government procurement, and private brands seeking reliable dermatology manufacturers.
5. Contract Manufacturing & Private Label Services
With a deep understanding of international markets, Taj Pharma offers:
- Third-party / contract manufacturing
- Private labeling with customized branding
- Customized formulations (strength, fragrance, base, packaging)
- Bulk supply for institutional tenders
Our speed, flexibility, and regulatory expertise ensure rapid go-to-market for clients.
6. Why Taj Pharma Is the Best Manufacturer, Supplier & Exporter of Creams & Ointments
✔ WHO-GMP & PIC/S compliant manufacturing
✔ Huge portfolio of dermatology & wound-care products
✔ Strong R&D for innovative formulations
✔ High capacity with timely global delivery
✔ Competitive pricing with premium quality
✔ Excellent regulatory dossier support
✔ Trusted by distributors & government agencies worldwide
With years of manufacturing excellence, Taj Pharma has built long-term partnerships across 40+ countries, delivering safe, effective, and affordable dermatology solutions.
Taj Pharma emerges as one of India’s most reputable and reliable manufacturers, suppliers, and exporters of high-quality dermatology creams, ointments, and gels. Our commitment to innovation, strict quality systems, and global regulatory compliance ensures that our partners receive world-class products meeting international standards.
Whether you are a distributor, tender participant, or private-label brand, Taj Pharma provides end-to-end pharmaceutical manufacturing solutions for all semi-solid formulations.






